# A Post-Marketing-Observational Study (PMOS) to Determine the Effectiveness of Combined Adalimumab Treatment and Active Supervised Training in Patients With Axial Spondyloarthritis (axSpA)

> **NCT03258814** · — · TERMINATED · sponsor: **AbbVie** · enrollment: 17 (actual)

## Conditions studied

- Axial Spondyloarthritis

## Interventions

- **BEHAVIORAL:** Active Supervised Training (AST)
- **BEHAVIORAL:** Standard of Care (SOC) Physiotherapy

## Key facts

- **NCT ID:** NCT03258814
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** TERMINATED
- **Start date:** 2017-12-08
- **Primary completion:** 2018-09-14
- **Final completion:** 2018-09-14
- **Target enrollment:** 17 (ACTUAL)
- **Why stopped:** Low or No Enrollment
- **Last updated:** 2019-10-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03258814

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03258814, "A Post-Marketing-Observational Study (PMOS) to Determine the Effectiveness of Combined Adalimumab Treatment and Active Supervised Training in Patients With Axial Spondyloarthritis (axSpA)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03258814. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*